Latest Breaking News On - Commercial supply - Page 4 : comparemela.com

Компания Хангук Корус готовится к поставке готовой продукции вакцины Спутник

Компания Хангук Корус готовится к поставке готовой продукции вакцины Спутник
primamedia.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from primamedia.ru Daily Mail and Mail on Sunday newspapers.

Russian direct investment fundCommercial supplyNews andRepublican clinical hospitalFrom are

SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer

SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer - Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT) - Follows recent appointments of Professor Ton Logtenberg as non-executive Chairman and Ray Barlow as Chief Executive Officer News provided by Share this article DUBLIN, Aug. 3, 2021 /PRNewswire/ SynOx Therapeutics Limited ( SynOx or the Company ), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces the appointments of Axel Mescheder, MD as Chief Medical Officer and Broes Naeye, PhD as Chief Technology Officer, as it accelerates activities to support a registrational trial of emactuzumab in the USA and EU.

United statesBroes naeyeGray barlowAxel meschederSynox therapeutics limitedSynox senior management teamSynox therapeuticsTenosynovial giant cell tumoursChief medical officerChief technology officerChief medicalHoffmann la rocheGlobal product supply leadCommercial supplyChief executive officerSynox senior management

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomMichel rudolphieCharles leeJoshua bartchAllison soss erika kayAnne donohoe nick opichMydecine innovations group incUniversity of albertaStock exchangeTrademark officeStrategic communicationsMydecine innovations groupDavid erritzoe at imperial college londonLeadgens lab

Altimmune Expands AdCOVID™ Manufacturing Collaboration With Lonza · BioBuzz

Altimmune Expands AdCOVID™ Manufacturing Collaboration With Lonza · BioBuzz
biobuzz.io - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biobuzz.io Daily Mail and Mail on Sunday newspapers.

United statesMartina ribar hestericovDirk oehlersAlberto santagostinoVipink gargVyjayanthi krishnanStacey jurchisonLonza group ltdAltimmune incSwiss exchangeUniversity of alabama at birminghamExchange commissionSingapore exchange securities tradingProduct development for altimmuneDedicated suiteCommercial supply

Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis

Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis Share Article Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020. BUDAPEST, Hungary (PRWEB) March 16, 2021 The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rheumatoid arthritis patients, before the first biological treatment initiation. This novel tool supports the decision making of stakeholders including rheumatologists, patients, payors, and drug developers. Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder affecting around 1% of the worldwide population. Clinical therapeutic options are still limited in their efficacy.

Brian lockhartMichelle collinsZsolt hollAegis pharmaceuticalsServier groupBusiness developmentVitro diagnostic medical device regulationApplied biosystemsGene expression taqmanArray cardThermo fisher scientificBiological business developmentCompanion diagnosticsCommercial supplyThermo fisherActive pharmaceutical ingredients